Gruber U F, Buser P, Frick J, Loosli J, Matt E, Segesser D
Eur Surg Res. 1977;9(5):303-10. doi: 10.1159/000127949.
Small doses of subcutaneous heparin and infusions of dextran both reduce the incidence of fatal pulmonary embolism after elective general surgery. But both methods have disadvantages. Therefore, the protection against deep vein thrombosis afforded by sulfinpyrazone, a drug which can be taken by mouth as well as by injection, was assessed in a prospective study of 119 patients undergoing elective general or urological surgery. The prophylactic administration of sulfinpyrazone was compared with the effects of small doses of sodium heparin and infusions of dextran-70. The 125I-fibrinogen test was carried out in all patients during their hospitalization. Deep vein thrombosis was diagnosed in 13 of 30 patients (43%) who received sulfinpyrazone, in 9 of 29 (31%) receiving dextran-70 and in 2 of 22 (9%) having subcutaneous heparin. The difference between the sulfinpyrazone and heparin groups was statistically significant (p less than 0.01). Sulfinpyrazone in the dose used in this trial was not effective in reducing the incidence of deep vein thrombosis during elective general surgery.
小剂量皮下注射肝素和输注右旋糖酐均可降低择期普通外科手术后致命性肺栓塞的发生率。但这两种方法都有缺点。因此，在一项对119例接受择期普通外科手术或泌尿外科手术患者的前瞻性研究中，评估了既能口服又能注射的药物磺吡酮预防深静脉血栓形成的作用。将磺吡酮的预防性给药与小剂量肝素钠和输注右旋糖酐70的效果进行了比较。所有患者在住院期间均进行了125I-纤维蛋白原试验。在接受磺吡酮的30例患者中有13例（43%）诊断为深静脉血栓形成，接受右旋糖酐70的29例中有9例（31%），接受皮下肝素的22例中有2例（9%）。磺吡酮组和肝素组之间的差异具有统计学意义（p小于0.01）。本试验中所用剂量的磺吡酮在降低择期普通外科手术期间深静脉血栓形成的发生率方面无效。
